Cost-utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis

被引：32
|
作者：
G. Kobelt
L. Jönsson
S. Fredrikson
机构：
[1] HDI France,
[2] Spéracèdes,undefined
[3] France,undefined
[4] Stockholm Health Economics Consulting,undefined
[5] Stockholm,undefined
[6] Sweden,undefined
[7] Department of Neurology,undefined
[8] Huddinge University Hospital,undefined
[9] Stockholm,undefined
[10] Sweden,undefined
来源：
The European Journal of Health Economics | 2003年 / 4卷 / 1期
关键词：
Keywords Multiple sclerosis; Cost; Utility; Interferon; Modeling;
D O I：
10.1007/s10198-002-0163-0
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：50 / 59
页数：9
相关论文
共 50 条
  • [31] Interferon β-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis
    Iarlori, C
    Reale, M
    De Luca, G
    Di Iorio, A
    Feliciani, C
    Tulli, A
    Conti, P
    Gambi, D
    Lugaresi, A
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2002, 123 (1-2) : 170 - 179
  • [32] Fatigue in Treated and Untreated Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
    Yaldizli, Oe
    Katsarava, Z.
    Vago, S.
    Limmroth, V.
    Putzki, N.
    [J]. AKTUELLE NEUROLOGIE, 2008, 35 (09) : 425 - 429
  • [33] Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
    Imani, Ali
    Golestani, Mina
    [J]. IRANIAN JOURNAL OF NEUROLOGY, 2012, 11 (03) : 87 - 90
  • [34] COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMERATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL
    Silva Miguel, L.
    de Sa, J.
    Pinheiro, B.
    Acosta, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A758 - A758
  • [35] DIMETHYL FUMARATE VERSUS FINGOLIMOD AND TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA: A COST-UTILITY ANALYSIS
    Ordonez, J. E.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A194 - A194
  • [36] COST-UTILITY ANALYSIS OF DISEASE-MODIFYING DRUGS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN IRAN
    Imani, A.
    Golestani, M.
    Tabrizi, J. S.
    Janati, A.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A624 - A624
  • [37] Cost-Utility Analysis Comparing Ocrelizumab vs Rituximab in the Treatment of Relapsing-Remitting Multiple Sclerosis: The Colombian Perspective
    Navarro, Cristian E.
    Betancur, John E.
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 83 - 91
  • [38] COST-UTILITY ANALYSIS OF ALEMTUZUMAB VERSUS NATALIZUMAB FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: US PAYER PERSPECTIVE
    Smith, A.
    Hashemi, L.
    Ma, I
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A431 - A431
  • [39] Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
    Vazquez Gomez, Lazaro Aurelio
    Hidalgo Mesa, Carlos
    Broche Perez, Yunier
    Valdes Morales, Yanet
    [J]. MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2022, 20 (05): : 825 - 833
  • [40] COST-UTILITY ANALYSIS OF DIMETHYL FUMARATE VERSUS FINGOLIMOD AND TERIFLUNOMIDE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA
    Ordonez, J.
    Serafini, P.
    Machado, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A434 - A434
12345